CCL2 and chronic kidney disease: Interestingly, FGF19 treatment reduced significantly the expression levels of all these inflammatory markers (Foxo1, Myd88, Mcp1, Il-6, Tnfα, and Il-1β) in the livers of CKD mice (Fig. 5A–F).